Therapeutic Action
Sedating H1 antihistamine
PDF page 484
Loading InternPractice…
Drug reference
Sedating H1 antihistamine
PDF page 484
Agitation or aggressive behaviour in patients with acute or chronic psychosis, in combination with haloperidol
PDF page 484
Administer with caution and monitor use: in older patients; in patients with prostate disorders, closed-angle glaucoma, epilepsy, orthostatic hypotension, severe renal or hepatic impairment; in patients taking central nervous system depressants (opioid analgesics, antipsychotics, sedatives, antidepressants, etc.) or drugs known to have an anticholinergic effect (atropine, amitriptyline, chlorpromazine, etc.). May cause: drowsiness, dizziness, headache, confusional state, hypotension, photosensitivity (protect skin from sun exposure); anticholinergic effects (dry mouth, constipation, blurred vision, tachycardia, disorders of micturition); tissue damage, including necrosis; rarely: seizures, extrapyramidal syndrome, neuroleptic malignant syndrome (unexplained hyperthermia with neuromuscular disorders), allergic reactions. Pregnancy and breast-feeding: avoid
PDF pages 484, 485
50 mg in 2 ml ampoule (25 mg/ml) for deep IM injection. NEVER ADMINISTER BY SC INJECTION.
PDF page 484
Adult: 25 mg, to be repeated after 30 minutes if necessary. If no response 30 minutes after the second dose, administer 50 mg (total dose max. 100 mg).
PDF page 484
Promethazine by IV route should only be used in intensive care unit, at a max. concentration of 1 mg/ml by infusion over 20 minutes using a central catheter or a large bore peripheral catheter (risk of necrosis and peripheral gangrene). Promethazine is not included in the WHO list of essential medicines.
PDF page 485
– Below 25 °C
PDF page 485
25 mg, to be repeated after 30 minutes if necessary. If no response 30 minutes after the second dose, administer 50 mg (total dose max. 100 mg).
PDF page 484